$RPTX
Repare Therapeutics Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021043943 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $278.0K $279.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.596M $6.741M $3.670M
YoY Change 57.05% 83.68% 256.31%
% of Gross Profit
Research & Development $25.36M $20.21M $8.951M
YoY Change 151.32% 125.73% 84.44%
% of Gross Profit
Depreciation & Amortization $369.0K $414.0K $200.0K
YoY Change 75.71% 107.0% 42.86%
% of Gross Profit
Operating Expenses $31.96M $26.95M $12.32M
YoY Change 126.85% 118.66% 109.4%
Operating Profit -$31.68M -$26.67M -$12.32M
YoY Change 124.88% 116.4% 109.4%
Interest Expense $86.00K -$56.00K $600.0K
YoY Change -80.89% -109.33% -233.33%
% of Operating Profit
Other Income/Expense, Net $79.00K -$63.00K $591.0K
YoY Change -82.13% -110.66% -230.18%
Pretax Income -$31.60M -$26.73M -$11.73M
YoY Change 131.59% 127.84% 85.08%
Income Tax -$708.0K -$421.0K $70.00K
% Of Pretax Income
Net Earnings -$30.89M -$26.31M -$11.80M
YoY Change 124.67% 122.96% 85.53%
Net Earnings / Revenue -11112.23% -9429.75%
Basic Earnings Per Share -$0.83 -$0.71
Diluted Earnings Per Share -$832.2K -$0.71 -$321.1K
COMMON SHARES
Basic Shares Outstanding 37.12M 37.04M
Diluted Shares Outstanding 37.12M 37.04M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $261.0M $293.6M $369.9M
YoY Change -24.98% -20.62%
Cash & Equivalents $261.0M $293.6M $370.1M
Short-Term Investments $7.200M $7.200M
Other Short-Term Assets $9.103M $2.129M $3.300M
YoY Change 7.09% -35.48%
Inventory
Prepaid Expenses $9.103M $2.129M
Receivables
Other Receivables
Total Short-Term Assets $280.4M $309.2M $377.3M
YoY Change -22.4% -18.04%
LONG-TERM ASSETS
Property, Plant & Equipment $4.165M $4.235M $2.453M
YoY Change -49.82% 72.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.008M $341.0K $894.0K
YoY Change 44.0% -61.86%
Total Long-Term Assets $15.27M $11.46M $4.467M
YoY Change 71.56% 156.62%
TOTAL ASSETS
Total Short-Term Assets $280.4M $309.2M $377.3M
Total Long-Term Assets $15.27M $11.46M $4.467M
Total Assets $295.6M $320.7M $381.7M
YoY Change -20.14% -16.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.860M $3.303M $3.576M
YoY Change 3.33% -7.63%
Accrued Expenses $12.08M $10.16M $4.200M
YoY Change 115.77% 141.93%
Deferred Revenue $8.925M $8.763M
YoY Change 315.12%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.41M $23.22M $9.797M
YoY Change 129.51% 137.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $53.98M $52.34M $58.30M
YoY Change -8.97% -10.22%
Total Long-Term Liabilities $53.98M $52.34M $58.30M
YoY Change -8.97% -10.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.41M $23.22M $9.797M
Total Long-Term Liabilities $53.98M $52.34M $58.30M
Total Liabilities $77.39M $75.56M $68.08M
YoY Change 11.52% 11.0%
SHAREHOLDERS EQUITY
Retained Earnings -$182.0M -$151.1M -$74.34M
YoY Change 103.22%
Common Stock $400.2M $396.2M $388.0M
YoY Change 2.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $218.3M $245.1M $313.7M
YoY Change
Total Liabilities & Shareholders Equity $295.6M $320.7M $381.7M
YoY Change -20.14% -16.0%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$30.89M -$26.31M -$11.80M
YoY Change 124.67% 122.96% 85.53%
Depreciation, Depletion And Amortization $369.0K $414.0K $200.0K
YoY Change 75.71% 107.0% 42.86%
Cash From Operating Activities -$32.77M -$18.05M $36.69M
YoY Change 62.97% -149.21% -703.45%
INVESTING ACTIVITIES
Capital Expenditures -$324.0K -$431.0K -$10.00K
YoY Change -32.5% 4210.0% -96.67%
Acquisitions
YoY Change
Other Investing Activities -$65.00K $312.0K
YoY Change
Cash From Investing Activities -$389.0K -$119.0K -$10.00K
YoY Change -18.96% 1090.0% -96.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 363.0K 452.0K 249.0M
YoY Change -121.35% -99.82%
NET CHANGE
Cash From Operating Activities -32.77M -18.05M 36.69M
Cash From Investing Activities -389.0K -119.0K -10.00K
Cash From Financing Activities 363.0K 452.0K 249.0M
Net Change In Cash -32.80M -17.72M 285.7M
YoY Change 47.15% -106.2% -4578.21%
FREE CASH FLOW
Cash From Operating Activities -$32.77M -$18.05M $36.69M
Capital Expenditures -$324.0K -$431.0K -$10.00K
Free Cash Flow -$32.45M -$17.62M $36.70M
YoY Change 65.3% -148.02% -734.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Type
DocumentType
10-Q
dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Entity File Number
EntityFileNumber
001-39335
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37117016
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
293635000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Trading Symbol
TradingSymbol
RPTX
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326184000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7160000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7526000
CY2021Q2 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2667000
CY2020Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2011000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58135000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
62000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2073000
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2038000
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2021Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2021Q2 us-gaap Other Receivables
OtherReceivables
3597000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
4153000
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2129000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6678000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
346552000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4235000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3948000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
218000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
212000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4631000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4674000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
341000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
288000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1412000
CY2021Q2 us-gaap Assets
Assets
320651000
CY2020Q4 us-gaap Assets
Assets
357086000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3303000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2251000
CY2021Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10337000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5975000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
758000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
697000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8763000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23223000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11014000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3540000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3308000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
48799000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55934000
CY2020Q4 us-gaap Liabilities
Liabilities
70256000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37109506
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37109506
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36902924
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36902924
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
357086000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5875000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10719000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103358000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151084000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
320651000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
245089000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
384313000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
385454000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3229635
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
309188000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2021Q2 us-gaap Liabilities
Liabilities
75562000
CY2021Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
279000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
445000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20205000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8951000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36714000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17583000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6741000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3372000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11978000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5555000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
26946000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
12323000
us-gaap Operating Expenses
OperatingExpenses
48692000
us-gaap Operating Expenses
OperatingExpenses
23138000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26667000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12323000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23138000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-94000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
595000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-125000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1136000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
38000
us-gaap Investment Income Net
InvestmentIncomeNet
102000
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
CY2020Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
4000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
591000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1142000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26730000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11732000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48284000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24280000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-421000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
70000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-558000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
CY2020Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-11802000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-47726000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-24403000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26309000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11802000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47726000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24403000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.56
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37036683
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4825214
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
135997000
CY2020Q2 rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
CY2020Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-11802000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
313656000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36977040
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-46129000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2057000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
389000
CY2020Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-12601000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
267653000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
449000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3183000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
245089000
us-gaap Profit Loss
ProfitLoss
-47726000
us-gaap Profit Loss
ProfitLoss
-24403000
us-gaap Share Based Compensation
ShareBasedCompensation
5240000
us-gaap Share Based Compensation
ShareBasedCompensation
660000
us-gaap Depreciation
Depreciation
734000
us-gaap Depreciation
Depreciation
403000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
748000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
305000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
13000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-1162000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-54000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
626000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
60000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4622000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2577000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
627000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
381000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-556000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
725000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
535000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1155000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
915000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
4509000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2371000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-272000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-9000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
44000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
133000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-238000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-292000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-445000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
50000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32285000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
26967000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1201000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3750000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-889000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
632000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
488000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
15000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
233760000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
632000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
249248000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1045000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32543000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
275127000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326396000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95005000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
293853000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
370132000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
293635000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7199
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9978000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9981000
CY2020Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
369933000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
218000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
199000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293853000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
370132000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
423000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
705000
rptx Initial Public Offering Costs In Accounts Payable
InitialPublicOfferingCostsInAccountsPayable
102000
rptx Initial Public Offering Costs In Accruals And Other Current Liabilities
InitialPublicOfferingCostsInAccrualsAndOtherCurrentLiabilities
1615000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
135997000
rptx Issuance Of Warrants And Conversion Into Common Stock During Period Value
IssuanceOfWarrantsAndConversionIntoCommonStockDuringPeriodValue
15000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9981000
CY2021Q2 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9978000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p>
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
us-gaap Variable Lease Cost
VariableLeaseCost
92000
CY2021Q2 us-gaap Lease Cost
LeaseCost
480000
CY2021Q2 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5700000
CY2020Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2584000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
925000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
934000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
184000
CY2021Q2 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
10337000
CY2020Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5975000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2778000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2771000
rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
424000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
165000
us-gaap Operating Lease Cost
OperatingLeaseCost
843000
us-gaap Operating Lease Cost
OperatingLeaseCost
330000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
54000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
39000
CY2020Q2 us-gaap Lease Cost
LeaseCost
205000
us-gaap Lease Cost
LeaseCost
958000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.08
us-gaap Variable Lease Cost
VariableLeaseCost
110000
us-gaap Lease Cost
LeaseCost
426000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
203283
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.11
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7962
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.13
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5258005
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.06
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4099545
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.11
us-gaap Operating Lease Payments
OperatingLeasePayments
605000
us-gaap Operating Lease Payments
OperatingLeasePayments
335000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
705000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M13D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.046
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4132123
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.39
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3505119
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1384616
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
869075
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.35
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
203283
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.11
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
266687
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55451
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7644
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.95
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.30
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.30
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0092
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0072
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7559
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26309000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11802000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47726000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24403000
CY2021Q2 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-26309000
CY2020Q2 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-11802000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-47726000
rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-24403000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37036683
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4825214
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36977040
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3229635
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.56

Files In Submission

Name View Source Status
0001564590-21-043943-index-headers.html Edgar Link pending
0001564590-21-043943-index.html Edgar Link pending
0001564590-21-043943.txt Edgar Link pending
0001564590-21-043943-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gsp5l3ss1paz000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-10q_20210630.htm Edgar Link pending
rptx-10q_20210630_htm.xml Edgar Link completed
rptx-20210630.xsd Edgar Link pending
rptx-20210630_cal.xml Edgar Link unprocessable
rptx-20210630_def.xml Edgar Link unprocessable
rptx-20210630_lab.xml Edgar Link unprocessable
rptx-20210630_pre.xml Edgar Link unprocessable
rptx-ex101_145.htm Edgar Link pending
rptx-ex102_144.htm Edgar Link pending
rptx-ex103_146.htm Edgar Link pending
rptx-ex104_177.htm Edgar Link pending
rptx-ex311_8.htm Edgar Link pending
rptx-ex312_7.htm Edgar Link pending
rptx-ex321_6.htm Edgar Link pending
rptx-ex322_9.htm Edgar Link pending
Show.js Edgar Link pending